What does acquired in-process research and development mean?

Specifically tracks cash payments for in-process research and development assets acquired through business combinations or direct asset purchases. In the biotech industry, this represents the cost of buying early-stage drug candidates or technology platforms. It is a critical indicator of R&D pipeline investment and future growth potential.

Spyre Therapeutics, Inc. SYRE Acquired in-process research and development

Acquired in-process research and development at other companies

Eli LillyLLY

$584M-62.8%

Ionis PharmaceuticalsIONS

$228.9M+1.6%

BiogenBIIB

$35M—

Segments

By segment

See full

Reportable Segment$46.89M+39.8%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfIntangibleAssets.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s acquired in-process research and development?: Spyre Therapeutics, Inc. (SYRE) reported acquired in-process research and development of $30M in Q1 2026.
What does acquired in-process research and development mean?: Specifically tracks cash payments for in-process research and development assets acquired through business combinations or direct asset purchases. In the biotech industry, this represents the cost of buying early-stage drug candidates or technology platforms. It is a critical indicator of R&D pipeline investment and future growth potential.